Lawrence Fong

Research interests

Publications

• Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes

  Cell · 2023 · https://doi.org/10.1016/j.cell.2023.02.021

• Single-cell RNA-seq reveals cell type–specific molecular and genetic associations to lupus

  Science · 2022 · https://doi.org/10.1126/science.abf1970

• Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox

  Immunity · 2021 · https://doi.org/10.1016/j.immuni.2021.11.015

• Tissue Determinants of Human NK Cell Development, Function, and Residence

  Cell · 2020 · https://doi.org/10.1016/j.cell.2020.01.022

• The DNA methylation landscape of advanced prostate cancer

  Nature Genetics · 2020 · https://doi.org/10.1038/s41588-020-0648-8

• Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

  Cell · 2020 · https://doi.org/10.1016/j.cell.2020.05.017

• Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz127

• Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

  Cancer Discovery · 2019 · https://doi.org/10.1158/2159-8290.cd-19-0980

• Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

  Cell · 2019 · https://doi.org/10.1016/j.cell.2019.02.016

• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

  Cell · 2018 · https://doi.org/10.1016/j.cell.2018.06.039

• TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

  Nature · 2018 · https://doi.org/10.1038/nature25501

• Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

  Nature Medicine · 2018 · https://doi.org/10.1038/s41591-018-0053-3

• Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1613683

• Systemic Immunity Is Required for Effective Cancer Immunotherapy

  Cell · 2017 · https://doi.org/10.1016/j.cell.2016.12.022

• Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

  Science Translational Medicine · 2014 · https://doi.org/10.1126/scitranslmed.3008211

• Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.24.1281

• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  Clinical Cancer Research · 2007 · https://doi.org/10.1158/1078-0432.ccr-06-2318

• Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

  Proceedings of the National Academy of Sciences · 2001 · https://doi.org/10.1073/pnas.141226398

• Dendritic Cells in Cancer Immunotherapy

  Annual Review of Immunology · 2000 · https://doi.org/10.1146/annurev.immunol.18.1.245

• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  Nature Medicine · 1999 · https://doi.org/10.1038/9525

Current projects

No projects listed.